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T
he data that would change the course of Jonathan 
Tilly’s career and cause an uproar in the ﬁeld of 
ovarian biology almost never saw the light of day. In 
Tilly’s cell death lab, postdoctoral fellow Tomoko Kaneko had 
twice repeated her experiments to kill off mouse egg cells, 
but something was wrong because the egg cell numbers were 
still high after treatment with a chemotherapy drug. Kaneko 
consulted another postdoc in the lab, Josh Johnson, and 
together they tried to determine if she had made a technical 
mistake or perhaps switched her control and experimental 
groups.
“All of us ‘knew’ that egg regeneration couldn’t be 
occurring,” says Johnson, referring to the long-held view 
that adult female mammals are born with a ﬁxed pool of 
oocytes, or egg cells, which gradually declines in number 
with age. The work appeared to be an anomaly, but Johnson 
prodded Kaneko to take it to their advisor’s ofﬁce. That 
2002 meeting was the birth of an ongoing controversy that 
has shaken up the ﬁeld of reproductive biology, with Tilly’s 
laboratory publishing data they interpret as evidence of egg 
regeneration occurring in adult mice.
Convinced that the dogma of a ﬁxed pool of oocytes 
is wrong, Tilly, a reproductive biologist at Massachusetts 
General Hospital in Boston, has brought this challenge forth 
almost single-handedly. His ﬁrst paper, published in Nature
in 2004 [1], and the exposure it received in the mainstream 
media, brought on a slew of harsh criticism and skepticism 
from senior researchers in the ﬁeld of ovarian biology. In the 
years since, Tilly’s group has published two more papers [2,3] 
extending the story, and his critics have published a handful 
of papers refuting his claims [4,5]. In addition, independent 
groups have published ﬁndings that both sides claim support 
their views. 
For most researchers familiar with the controversy, the 
matter is not resolved and continues to stimulate discussion 
and new work. But the debate has become highly polarized 
and somewhat adversarial, with most players falling into 
two camps—those who think Tilly’s challenge and the idea 
of regeneration hold merit and those who hold ﬁrm to the 
dogma and dismiss Tilly as misguided. The stakes for this 
debate are high—practically all research done in the ﬁeld of 
ovarian biology in the past 100 years has been grounded in 
the ﬁxed-pool dogma. More importantly, perhaps, this idea 
has also shaped the way in which doctors treat women for 
infertility and menopause. If the dogma were overturned, it 
would mean that current treatments for female reproductive 
problems—for example, infertility treatments after cancer 
therapy or for aging women, and for ovarian failure, a 
condition related to menopause—may be based on false 
assumptions.
“Controversy is a very vital part of the scientiﬁc process,” 
says Roger Gosden, an ovarian expert at Weill Cornell 
Medical School in New York City. “It’s the critical nature 
of science which gives it its strength and authority.” 
Though critical of Tilly’s interpretations, Gosden admits 
that the question of regeneration is so important to the 
ﬁeld of reproductive biology that it should be investigated 
thoroughly.
This particular controversy makes a compelling case study 
for exploring how challenges to scientiﬁc dogma proceed 
in today’s research climate. It carries historical perspective, 
because the ﬁeld experienced the same challenge roughly 75 
years ago. It also raises questions about challenging ideas in 
the information age, when new research breakthroughs are 
just a click away from patients’ ﬁngertips. Tilly’s conﬁdent, 
bold style raises the issue of whether a less pushy approach 
would meet less resistance. 
This controversy also highlights the problems with 
replicating studies to conﬁrm or refute ﬁndings. Whose 
burden is it to do these experiments, and under current 
pressures, how best to get that work done? What standard of 
evidence is needed to overturn an entrenched idea? 
Reigniting a Past Debate
In 1870, German anatomist Heinrich Wilhelm Gottfried von 
Waldeyer-Hartz ﬁrst proposed that oogenesis, the making 
of new oocytes, occurs before birth in female mammals 
and results in a ﬁnite number of oocytes that will decline 
during a lifespan. This view had been challenged by two 
researchers in the early 1920s and 1930s, when Lord Solomon 
“Solly” Zuckerman, then a young professor at University of 
Birmingham in England, undertook a series of experiments 
to investigate the challenge. He began his quest convinced 
the dogma was wrong and was inspired by the thought that 
“one ought to be able to promote oogenesis in a failing 
ovary...of a menopausal woman. This notion was more than 
enough bait to stimulate further enquiry.” [6].
Zuckerman then proceeded to spend two decades 
exploring the challenges to the dogma by using the new 
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histological techniques and knowledge about the cyclical 
nature of the female sexual hormones. In 1950, he gave 
a seminal talk at the Laurentian Hormone Conference of 
the American Association for the Advancement of  Science 
(AAAS) in Franconia, New Hampshire [7], in which he 
summarized his body of work before the leading reproductive 
biologists, many of whom were anticipating he would provide 
evidence of oogenesis in adult life. Instead, Zuckerman 
produced a mountain of evidence that reinforced the 
dogma. The chair of the session concluded with the remark 
“Waldeyer must have been right after all,” and the audience 
ﬁled out with a feeling that the question was resolved.
Both Waldeyer and Zuckerman’s work, the bricks of the 
dogma’s foundation, rests largely on the simple process 
of counting egg cells—or more speciﬁcally, the follicle 
structures that encase egg cells inside the ovary—over the 
course of an animal’s lifetime. 
Such follicle counting would seem relatively 
straightforward. But how to properly count these tiny 
structures—which grow, change form, and die off over a 
monthly cycle inside a rather inaccessible and complex 
organ—has been the subject of much debate from the 1880s 
onward (for a primer on egg development, see Figure 1). 
Add to that the logistical and ethical impossibilities involved 
in investigating oocyte numbers from healthy human 
ovarian tissue, and simple counting starts to seem rather 
vexing.
The current controversy (Box 1) has some striking 
differences from that of Zuckerman’s time. Seventy-ﬁve years 
ago, the debate took place almost exclusively within the 
halls of academia and in the literature—removed from the 
public consciousness. Infertility treatment did not yet exist. 
Zuckerman and his peers argued over the scientiﬁc evidence 
but did not touch upon implications for patient care or 
patient concerns.
“It makes a huge difference if a controversy is conducted 
in private or in public,” says John Durant, who directs the 
MIT museum in Cambridge, Massachusetts, and studies the 
relationship between science and the public. With medically 
relevant science, he says, there is the potential for the public 
to seize on ﬁndings that could be premature at best and false 
at worst. 
“Once you’ve interested the public in what you are doing, 
you cannot shut the door,” says Durant. Indeed, many of 
Tilly’s critics are most upset that his ﬁrst paper’s ﬁndings 
were splashed across the headlines of major newspapers and 
that Tilly was freely discussing the potential human health 
implications in the media. 
The current trend in fertility treatment—which focuses on 
preserving fertility in both cancer patients and aging women—
adds to the consternation of Tilly’s critics. David Albertini, an 
oocyte expert at Kansas University Medical Center in Kansas 
City, reports meeting an increasing number of women patients 
at conferences on fertility preservation who have educated 
themselves on techniques not yet available in fertility clinics.
Albertini, one of Tilly’s most vocal critics, says it would have 
been healthier for the ﬁeld if Tilly’s ﬁrst announcement had 
been more “subtle” both in the literature and in the media. 
“Phones were ringing off the hook with patients calling 
clinics long before the scientiﬁc community had a chance to 
evaluate that work,” he says. 
Tilly feels his comments to the press were an appropriate 
balance of optimism and caution, and defends his stance: 
“Yes, I tell people what I think this work may achieve for 
humans. How can you get criticized for speculating about the 
meaning of your work?” 
doi:10.1371/journal.pbio.0050338.g001
Figure 1. Oocyte Development
During the ﬁfth month of fetal development in female humans, roughly 7 million oocytes are produced within the ovaries from germline stem cells. 
These primary oocytes will be surrounded by ﬂattened cells to form primordial follicles by the seventh month. At birth, many of these oocytes will have 
degenerated, leaving roughly 2 million oocytes. Follicle development then ceases until puberty, when follicles mature during each ovulation cycle. 
Only a fraction of these oocytes will be ovulated and potentially fertilized between puberty and menopause, roughly 400–500 cells if a woman ovulates 
regularly each month. The rest of the oocytes remain in the ovaries as immature oocytes. The two types of follicles—immature follicles and those 
destined to be ovulated—play different roles during the menstrual cycle.
Some of the immature follicles produce signals that, along with hormones secreted by the brain, support the development of a subset of 4–10 
primary follicles, which grow in size. Eventually, one follicle becomes dominant, grows larger, ruptures through the ovary wall, and releases its egg cell 
into the reproductive tract. After ovulation, a wave of cell death, or atresia, destroys some of the follicles that were growing, but not ovulated. Over a 
lifetime, this monthly cycle of ovulation and cell death depletes the population of immature oocytes to the point where they can no longer support 
ovulation, and menopause ensues.
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In contrast to arguments occurring behind the ivory tower 
walls, Durant says publicized debates become less predictable 
and more polarized. Evelyn Telfer, an oocyte researcher 
at University of Edinburgh, UK, points out another key 
difference facing researchers today: “Universities are 
operating within a market environment now, and there is 
more pressure to get your results into the public domain and 
get patents,” she says. 
Risking Reputation or Pursuing a Vision?
A good portion of the skepticism directed at Tilly’s work 
stems not so much from the scientiﬁc arguments, but from 
the very fact that only one group is challenging the dogma. 
Many scientists are reluctant to even weigh in ofﬁcially on 
the debate until other groups come forward with similar, 
supporting work.
“What anyone publishes is not really the corpus of 
scientiﬁc knowledge unless it can be veriﬁed,” says Gosden. 
“You don’t get a paradigm change until you have a consensus 
of expert opinion,” he says, and that is certainly not the 
case here. This follows physicist and science historian 
Thomas Kuhn’s view of scientiﬁc revolutions—that many 
inconsistencies must build up in a ﬁeld of science before a 
paradigm shift can occur. 
The Kuhn model of paradigm shifts describes how most 
central ideas in science get revised or overturned, but there is 
another model that some would argue is equally valid, if rarer: 
the “lone voice in the wilderness” of a single scientist pushing 
a revolutionary idea forward. There are notable examples of 
lone voices who both succeeded and failed in overturning 
an idea. Stanley Prusiner’s hypothesis that aberrant protein 
structures called prions could cause infection initially lost 
him his bid for tenure at the University of California at San 
Francisco and signiﬁcant funding from the Howard Hughes 
Medical Institute, but eventually won him a Nobel prize in 
physiology or medicine in 1997. The cold fusion work of the 
late 1980s, which was never replicated to the satisfaction of 
the nuclear physics community, eventually resulted in Martin 
Fleischmann and Stanley Pons dropping out of academia.
“There’s a ﬁne line between being a maverick and a genius 
prescient person,” says Durant. Currently, Tilly is gingerly 
straddling that line, which can mean the difference between 
receiving the highest scientiﬁc honors or the scorn of your 
peers.
Box 1. The Making of a Controversy
The ﬁrst paper Tilly, published in Nature in March 2004, was 
based on the fact that follicle numbers did not add up in the 
mouse chemotherapy experiments that his postdoc Josh Johnson 
repeated [1]. The authors postulated that an ovarian stem cell must 
be regenerating oocytes. In the next paper, published in Cell in July 
2005 [2], the group reported that stem cells from the bone marrow 
replenish the egg supply in the chemotherapy-treated mice. 
In 2006, two reports were published from other groups, one 
of which appeared to support Tilly’s hypothesis and one which 
appeared to refute it. Roger Gosden and Amy Wagers published a 
study in Nature that was designed to test whether such putative 
stem cells contributed to ovulated eggs [4]. Their experiments 
showed that mice sharing a circulatory system, and presumably 
any such bone marrow-derived stem cells, only ovulated their 
own eggs. At this point, many scientists in the ﬁeld felt the 
issue had been laid to rest since, in their view, the ultimate 
physiological signiﬁcance of egg regeneration would be to 
contribute new ovulated eggs and offspring. But Tilly and other 
independent scientists pointed out several technical ﬂaws with 
the Wagers study. Tilly’s biggest complaint was that the study did 
not include an analysis of what was happening inside the ovaries 
of these animals—to show the presence or absence of donor-
derived stem cells or oocytes—but only looked at ovulated eggs. 
The other paper published in 2006 bolstered Tilly’s work. Jeff 
Kerr and Jock Findlay, reproductive biologists from Monash 
University and Prince Henry’s Institute of Medical Research, 
respectively, in Clayton, Australia, produced a quantitative 
study that tracked healthy follicles in mice through adult life
[10]. Although they found no evidence for germline stem cells 
or another mechanism to explain their results, the team’s data 
supported the hypothesis that follicle renewal was occurring in 
the adult mice.
Tilly sees this study as a replication of sorts of the follicle 
numbers ﬁnding from his ﬁrst paper. Others in the ﬁeld, although 
hard-pressed to ﬁnd technical fault with Kerr and Findlay’s 
experiments, say the results are open to different interpretations 
based on how the statistical analysis was performed.
doi:10.1371/journal.pbio.0050338.g002
Jonathan Tilly’s research at Massachusetts General Hospital 
in Boston has stoked a controversy about whether female 
mammals can renew egg cells.
(Image credit: Massachusetts General Hospital public affairs)
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“Jonathan is very good at putting his points across and 
defending his work very forcibly, and he has a right to do 
so,” says Telfer. “But he can upset some people because he’s 
presented himself as a misunderstood visionary and that 
everyone else just doesn’t ‘get it.’”  Telfer led the publishing 
of one of the most scathing commentaries on Tilly’s ﬁrst 
paper [8], but has since softened her stance toward his work, 
noting that he has addressed well some of the scientiﬁc 
criticisms of his work in follow-up studies.
Tilly knows what he’s risking in pursuing his challenge to 
the dogma, but says he’s decided to commit his laboratory to 
this line of work, because the issue remains unresolved, the 
answer is too important, and he has too much data to believe 
he is wrong. It has changed the type of junior scientists who 
apply to his group, weeding out those who don’t want to get 
involved in the controversy, but that isn’t all bad in his view. 
“This isn’t something that someone weak of conviction 
or heart would want to take on,” he says. “You have to be 
conﬁdent about your abilities to do this work and remain 
fairly insulated from criticism.” 
And some argue that science can beneﬁt from big 
personalities. “Whether concepts in biology and medicine 
evolve has a lot to do with whether or not there are strong-
voiced, strong-willed champions,” says David Scadden, 
director of the Harvard Stem Cell Institute and a co-author 
on Tilly’s bone marrow study. Tilly claims he didn’t seek out 
this controversy, that he stumbled into it from his group’s 
work in cell death, but it’s clear he enjoys the limelight to a 
certain extent. It’s also clear that circumstances of his position 
offered him some protection to become the squeaky wheel. 
His group had already distinguished itself with a decade of 
solid research in the apoptosis ﬁeld, and he’d been promoted 
from assistant to associate professor within Harvard Medical 
School. His institution enjoys a large amount of philanthropic 
support, making its researchers somewhat less dependent on 
federal grant money.
Such security stands Tilly in stark contrast to his former 
postdoc, Johnson, who moved to Yale University School of 
Medicine as an assistant professor in 2005. Johnson’s lead 
authorship on the two high-proﬁle publications from his 
postdoc project helped his search for a faculty position, 
but funding for extending his postdoctoral work has been 
extremely difﬁcult to come by. 
“There is a skeptical undercurrent in the ﬁeld that 
occasionally comes to the surface,” Johnson says. “I have 
received advice at meetings from senior researchers in 
the ovarian ﬁeld to distance myself from Jonathan and my 
postdoctoral work in general, at least for now.” As such, 
The current climate of scientiﬁc debate has been changed by 
modern inﬂuences on public communication and by funding 
and publication pressures, which have also complicated the 
process of replicating results. 
After Tilly’s ﬁrst two papers were published, the implications 
spurred high interest in the ﬁeld for ﬁnding a way to replicate 
or refute his ﬁndings—but exactly repeating his group’s mouse 
experiments could easily take another group ﬁve years or more. 
Instead, Gosden decided to appeal to several hematology 
groups, including Wagers’, to ﬁnd a collaborator who might 
have the “spare” animals and resources to test more quickly the 
idea that stem cells from bone marrow were responsible for 
regenerated oocytes. 
“Replication is a huge problem—all of that work is not funded 
and not fundable, especially in today’s climate,” Wagers says. 
Exact repetition of experiments will not ﬂy, Wagers adds, 
unless you have somehow extended the original study. “But 
if you have discovered something fundamental, it should be 
arrived at in multiple ways by multiple groups—that is the mark 
of an important discovery.”
Tilly, however, does not count the Gosden and Wagers paper 
as a valid attempt at replicating his work—mainly because it did 
not do the same types of experiments his group did and because 
the group used a different strain of green ﬂuorescent protein 
(GFP)-marked mice. (In Tilly’s strain, only the germline cells are 
ﬂuorescent green and in the Wagers’ mouse line, every cell 
expresses the green dye.)
But his biggest gripe with the study brings up the issue of 
who should shoulder the burden of verifying or refuting claims 
made by another group. In the Wagers paper, the authors 
noted: “Although cells derived from circulation may be found 
within the ovaries of parabiotic animals, these engrafted cells 
exhibit exclusively haematopoietic fates, and probably represent 
circulating blood cells known to inﬁltrate all tissues...as immune 
responders.” [4]. 
Tilly’s critics seized on this sentence as “proof” that the bone 
marrow–derived cells he was seeing in mice ovaries were not 
regenerated oocytes, but rather, immune cells activated to offset 
the chemotherapy-induced damage. At the time the Wagers 
paper  was published, Tilly was incensed that such a statement 
could appear in a Nature paper without supporting data, such as 
immune cell markers, to back it up.
“The burden isn’t on us to go back and prove their claim 
is true,” he said in a 2006 interview. But eventually his group 
did end up addressing the issue experimentally, because the 
“immune cell” criticism persisted. His group’s latest publication 
includes an experiment showing that the GFP-marked cells 
from their mice, some of which end up in the bone marrow 
transplant recipient’s ovaries, do not express immune cell 
markers [3]. 
Tilly acknowledges that a direct repeat of his group’s body of 
work is too high a bar to set, but he says individual experiments 
could easily and inexpensively be repeated. For example, an 
experiment from the 2005 Cell paper [2], which treats mice with 
a chemotherapy drug and then counts follicles afterward, could 
be done in two weeks for a few hundred dollars, he says. Why no 
one has bothered to do it yet, he says, is more telling about his 
critics’ motives than a lack of resources.
“They don’t want to do it because they might ﬁnd something 
they don’t want to ﬁnd,” says Tilly. “If someone tried to do this 
experiment and could not repeat our results, for this particular 
topic, that would be very publishable in a high-proﬁle journal.”
Troubles with replicating work, which have especially plagued 
the stem cell ﬁeld, often cast doubts on certain groups but also 
occur more commonly than scientists like to admit [11]. “The 
ideal is that we will do this experiment and get the predicted 
result or not, which will conﬁrm or falsify our hypothesis,” says 
Durant of the MIT museum. “But in practice, the attempts are not 
so straightforward. The question of what counts as a critical test 
and any given outcome of the test are open to debate.”
Box 2. Wrestling with Replication 
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Johnson has broadened his interests and research program 
to the general effects of stress on oocyte quality, ovarian 
function, and fertility. He admits he’s a little jealous of 
colleagues whose transitions from postdoc to professor were 
smoother than what he’s experienced.
“But I unreservedly believe in the data we got.” He also says 
he would volunteer for the project if he were back in Tilly’s 
ofﬁce again. “The data is there, the question is there, and 
you have to follow it up,” he says. “It’s not about the hype or 
the politics or the hurt feelings—honestly it’s the answer that 
matters: how does the ovary really work?”
Tilly does worry that the controversy will affect his next 
tenure promotion and that it may impede the publication 
record of his fellows. And he hopes he won’t ﬂee academia 
like other lone voices who turned out to be wrong. But, he 
says it’s not in his personality to back down from a scientiﬁc 
puzzle. “It’s my responsibility as a scientist to go after it and 
ﬁgure it out.”
It took Prusiner decades to fully convince his critics about 
prions and change a ﬁeld’s view of infectious mechanisms. 
Sometimes Tilly feels as if his critics want “20 years of work in 
four years”. 
The latest piece of the puzzle, published in August 2007, 
showed that mice receiving bone marrow transplants after 
chemotherapy treatment recover fertility and that donor-
derived cells appear as immature follicle structures in the 
recipient mouse’s ovary [3]. Although none of the treated mice 
gave birth to pups arising from donor-derived eggs (all pups 
were genetically matched to the mother), Tilly interprets the 
appearance of the donor-derived immature oocytes as evidence 
for regeneration of immature “helper egg follicles,” which 
restore fertility in what would otherwise be sterile animals.
Also this year, Albertini and his colleague David Keefe of 
the University of South Florida in Tampa published a study 
analyzing adult human ovarian tissue for genetic markers 
of meiosis and germ cell proliferation, both of which 
would be expected if a germline stem cell were present and 
regenerating oocytes in adult human ovaries [5]. They found 
no evidence of such markers. 
Albertini now characterizes the debate as lingering among 
physicians, but among basic researchers as a closed case 
against women being able to regenerate oocytes. Many others, 
including Telfer and Gosden, say the door is still open for 
more work to be done and that the “helper follicle” idea 
may very well hold water. But no matter which way the dice 
eventually roll for Tilly’s ideas, the debate itself has already 
changed the ﬁeld. 
Harmful or Healthy?
Telfer goes so far as to say that Tilly “has done a service 
to the ovarian biology community.” She says his work has 
stimulated new approaches to her laboratory’s studies on 
oocyte maturation. And she credits the debate for spawning 
new questions about the “helper follicle” hypothesis, the 
timing of follicle formation, and whether oocytes are ﬂexible 
to manipulation, even if they are in a ﬁxed pool.
Gosden agrees the controversy has cast a spotlight on new 
questions that would not have been investigated otherwise. 
And he doesn’t see any harm in revisiting the dogma with 
new technologies, quoting T.S. Eliot’s poem Little Gidding, 
“At the end of all our exploring/Will be to arrive where we 
started/And know the place for the ﬁrst time.”
Amy Wagers, a stem cell biologist at Harvard’s Joslin 
Diabetes Center in Boston, points to other controversies in 
which the original interpretation proved wrong but led to 
the discovery of a novel process, nonetheless. For example, in 
stem cell biology, claims of transdifferentiation—one cell type 
switching fates to become another cell type—eventually gave 
way to the ﬁnding that cells were fusing to become functional 
hybrid cells. “We now know that cells can do something we 
didn’t know before, and it raises important questions about 
whether cell fusion is important in normal physiology or in 
disease,” says Wagers.
But Albertini says the controversy has been “devastating to 
the ﬁeld as a specialty area” because it hasn’t been formally 
resolved. He and others such as Keefe feel strongly that the 
medical community has been misled into believing there 
are implications for human fertility preservation. When 
future therapies fail to appear, it will tarnish the image of 
reproductive biologists. Albertini also sees the hunt for 
ovarian germline stem cells as a distraction that has diverted 
substantial time and resources to repeating work that he 
contends was not up to par in the ﬁrst place (Box 2).
Although these arguments play out in the literature and 
conference presentations, both camps have alternately 
charged that certain experiments from the other side could 
not be repeated or that data have been suppressed. Though 
some fear that such accusations are damaging the ﬁeld, MIT’s 
Durant counters that it’s a normal part of scientiﬁc discourse 
and controversy. 
“Scientists are very much like everyone else when caught up 
in a controversy and will often reach for any and all resources 
to support their position and undermine their opponent’s 
position,” he says. In fact, it’s been shown that there is an 
asymmetry that exists between the type of rhetoric scientists 
use to support their own point of view and the rhetoric used 
to describe their opponent’s point of view [9]. Or, as Durant 
sums up, “I have reasons, but you have inﬂuences.”
Telfer says that the presentation of the debate has been too 
adversarial and has been cast in absolute terms. “The debate 
has set up just to be regeneration or not, and that’s a shame 
because that’s not really how science should work,” she says, 
noting that interesting results have been obscured by the 
shouting over regeneration.
Durant notes that this controversy may not ever come to a 
clear end like the deﬁning moment of Zuckerman’s 1950 talk. 
“Sometimes the world just moves on, the actors lose interest, 
and the ﬁckle media turn to another hot topic,” he says. 
“Science is a lot more like the rest of life—it’s messier and 
more ambiguous than cartoons of science portray.”  
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